Researchers from a consortium of international institutions have made a significant breakthrough in understanding the complex life cycle of the…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for…
Read More
Terray’s TerraBind Delivers 26x Faster Inference and Enhanced Accuracy, Challenging Diffusion-Based AI Models in Drug Discovery
In a significant development poised to reshape the landscape of AI-driven drug discovery, Terray Therapeutics, a Los Angeles-based startup, has…
Read More
How Digital Tools and AI Are Accelerating Drug Discovery
The landscape of pharmaceutical innovation has long been characterized by arduous timelines, exorbitant costs, and a high probability of failure,…
Read More
Closing the Information Gap: ETH Zurich Team Integrates Function and Binding in One Drug Screening Assay
A pioneering team of researchers from ETH Zurich and Karolinska Institutet has unveiled a groundbreaking cross-linking MALDI mass spectrometry (MS)…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry, perpetually navigating a landscape of escalating costs and protracted timelines, faces a critical juncture where innovation is…
Read More
From list price to net price: How finance leaders decode real drug costs
In the complex landscape of the healthcare industry, public discourse surrounding drug pricing frequently begins and ends with the list…
Read More
Accelerating drug discovery with “paradigm shifting” AI model
A groundbreaking multi-institutional collaboration, spearheaded by researchers at Michigan State University (MI, USA), has unveiled a novel machine-learning-based drug discovery…
Read More
Eli Lilly’s Foundayo Secures FDA Approval, Challenging Novo Nordisk’s Oral Obesity Drug Dominance
The United States Food and Drug Administration (FDA) has granted approval to Eli Lilly and Company’s novel oral glucagon-like peptide-1…
Read More
Telomir Pharmaceuticals Submits Investigational New Drug Application for Telomir-1 to FDA for Advanced Triple-Negative Breast Cancer
Telomir Pharmaceuticals has taken a significant stride in its mission to combat advanced and metastatic triple-negative breast cancer (TNBC) by…
Read MoreYOU MAY HAVE MISSED
